“BRANDED GENERICS” AS A STRATEGY TO LIMIT CANNIBALIZATION OF PHARMACEUTICAL MARKETS

This paper demonstrates how, by introducing a generic version of its previously-patented product, a branded firm can influence the equilibrium in the generic segment of the market for the product. This in turn can increase the firm’s profits from selling the branded version. We then use structural estimates from previous literature to calculate the magnitude of the effects in the generic and branded segments.

MoreLess

Year of publication:	2005-05
Authors:	Ward, Michael R. ; Reiffen, David
Institutions:	Department of Economics, College of Business Administration
Subject:	Pharmaceuticals \| Generic Drugs \| Oligopoly \| Strategy

freely available

Full text |

More access options

Check Google Scholar

In German libraries (KVK)

I need help

More details

Extent:	application/pdf
Series:	Working Papers.
Type of publication:	Book / Working Paper
Notes:	38 pages
Classification:	L13 - Oligopoly and Other Imperfect Markets ; L41 - Monopolization; Horizontal Anticompetitive Practices ; L65 - Chemicals; Rubber; Drugs; Biotechnology ; D43 - Oligopoly and Other Forms of Market Imperfection
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10005230146